Neurocrine Biosciences is Under Heavy Accumulation, The One Chart that Matters

Neurocrine Biosciences Stock Reveals Strong Demand

Institutional volumes reveal plenty. For the past 6 months, NBIX has enjoyed heavy institutional support.
Each green bar signals unusually large volumes in NBIX shares, pushing the stock higher:

Plenty of health care names are under accumulation right now. But there’s a powerful fundamental backdrop going on with Neurocrine.

Neurocrine Biosciences Fundamental Analysis

Institutional support coupled with a healthy fundamental backdrop makes this company worth investigating. As you can see, NBIX has had positive sales & EPS growth in recent years:

• 3-year sales growth rate (+24.1%)
• 3-year EPS growth rate (+325%)

Source: FactSet

EPS is estimated to ramp higher this year by +92.6%.

Now it makes sense why the stock has been powering to new heights. NBIX is an earnings juggernaut.

Marrying great fundamentals with our proprietary software has found some big winning stocks over the long-term.

Neurocrine Biosciences has been a top-rated stock at MAPsignals. That means the stock has unusual buy pressure and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis.

It’s made the rare Top 20 report a few times recently. The blue bars below show when NBIX was a top pick…cutting through the noise:

Tracking unusual volumes reveals the power of money flows.

This is a trait that most outlier stocks exhibit…the superstars.

Neurocrine Biosciences Price Prediction

The NBIX rally began many months ago. Big Money buying in the shares is signaling to take notice. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio.

Disclosure: the author holds no position in NBIX at the time of publication.

If you are a Registered Investment Advisor (RIA) or are a serious investor, take your investing to the next level, learn more about the MAPsignals process here.